[SF Business Times ] Three takeaways from Gilead’s Hepatitis C challenge

1. It’s all about price — even when it’s not: Even before Foster City-based Gilead Sciences Inc., led by CEO John Martin, launched its hepatitis C drug Sovaldi for $1,000 a pill, critics pounced.

[button title=”Read More” link=”http://www.bizjournals.com/sanfrancisco/print-edition/2014/07/18/three-takeaways-from-gileads-hepatitis-c-challenge.html” target=”_blank” size=”” color=”” class=””]